publication venue for
- Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. 2021
- Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma. 2019
- Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab. 2019
- Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. 2016
- Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. 2013
- Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology. 2006
- Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy.. 23. 2022
- Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report.. 23. 2021
- Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.. 23. 2021
- A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).. 22. 2021
- Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma.. 21. 2020
- A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.. 19. 2018
- Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.. 19. 2017
- Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.. 19. 2017
- Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery.. 18. 2017
- The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.. 18. 2017
- The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.. 18. 2017
- Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma.. 18. 2016
- Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.. 17. 2016
- Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.. 17. 2015
- Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.. 16. 2015
- Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway.. 15. 2014
- Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.. 15. 2014
- Extended-duration therapy in advanced non-small-cell lung cancer: promise and pitfalls.. 11. 2010
- Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity.. 11. 2010
- Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.. 9. 2008
- FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy.. 6. 2005
- Promising developments in targeted therapies for non-small-cell lung cancer.. 4. 2002
- Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients.. 3. 2002
- Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.. 3. 2001
- Small molecule inhibitors of the epidermal growth factor receptor in patients with non-small-cell lung cancer: an update of clinical data from the 2001 American Society of Clinical Oncology meeting.. 2. 2001
- Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. 2010
- Non-rash skin toxicities associated with novel targeted therapies. 2006
- Current status of mammalian target of rapamycin inhibitors in lung cancer. 2005
- Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. 2004
- Computerized tomographic nodule heterogeneity: present and future impact on indications for sublobar resections. 2004